-1.43%
5.18%
16.69%
13.68%
60.62%
-8.50%
98.01%
AI Spotlight on BLFS
Company Description
BioLife Solutions, Inc.develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials.The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services.It markets and sells its products directly, as well as through third party distributors.
BioLife Solutions, Inc.was incorporated in 1987 and is headquartered in Bothell, Washington.
Market Data
| Last Price | 27.3 |
| Change Percentage | -1.43% |
| Open | 27.65 |
| Previous Close | 27.7 |
| Market Cap ( Millions) | 1267 |
| Volume | 166354 |
| Year High | 29.46 |
| Year Low | 14.5 |
| M A 50 | 26.31 |
| M A 200 | 23.29 |
Financial Ratios
| FCF Yield | 0.45% |
| Dividend Yield | 0.00% |
| ROE | -13.97% |
| Debt / Equity | 12.07% |
| Net Debt / EBIDTA | -70.58% |
| Price To Book | 3.87 |
| Price Earnings Ratio | -27.39 |
| Price To FCF | 224.14 |
| Price To sales | 10.27 |
| EV / EBITDA | -59.17 |
News
- Jan -29 - BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?
- Jan -24 - Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
- Jan -22 - BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why
- Jan -13 - BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations
- Jan -08 - BioLife Solutions price target raised to $31 from $28 at Northland
- Dec -16 - BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
- Nov -14 - BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary
- Nov -13 - BioLife Solutions, Inc. (BLFS) Q3 2024 Earnings Call Transcript
- Nov -12 - BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates
- Nov -12 - BioLife Solutions Reports Third Quarter 2024 Financial Results
- Nov -12 - BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary
- Oct -31 - BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024
- Oct -21 - Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
- Sep -17 - Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
- Aug -20 - BioLife Is Cleaning Ship
- Aug -09 - BioLife Solutions, Inc. (BLFS) Q2 2024 Earnings Call Transcript
- Aug -08 - BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
- Aug -08 - BioLife Solutions Reports Second Quarter 2024 Financial Results
- Jul -25 - BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
- Jul -12 - What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing'
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Cell Processing - Product
Expected Growth : 14.0 %
What the company do ?
Cell Processing - Product from BioLife Solutions, Inc. is a cryopreservation solution for preserving living cells and tissues at very low temperatures.
Why we expect these perspectives ?
The 14.0% growth in Cell Processing - Product from BioLife Solutions, Inc. is driven by increasing demand for regenerative medicine, adoption of cell-based therapies, and expansion of biobanking services. Additionally, advancements in cell preservation and cryopreservation technologies, as well as growing investments in cell and gene therapy research, contribute to the segment's growth.
Segment n°2 -> Freezer and Thaw - Product
Expected Growth : 15.0 %
What the company do ?
Freezer and Thaw - Product from BioLife Solutions, Inc. is a cryopreservation tool that preserves and thaws living cells and tissues for research and therapeutic applications.
Why we expect these perspectives ?
BioLife Solutions' Freezer and Thaw product growth is driven by increasing demand for regenerative medicine, cell and gene therapy, and biobanking applications. The 15.0% growth rate is also fueled by the product's ability to preserve and protect sensitive biological materials, as well as its compatibility with various cryogenic storage systems.
Segment n°3 -> Biostorage Services - Service
Expected Growth : 17.0 %
What the company do ?
Biostorage Services from BioLife Solutions, Inc. provides secure, temperature-controlled storage and logistics for biological materials, including cells, tissues, and biomolecules.
Why we expect these perspectives ?
Biostorage Services' 17.0% growth is driven by increasing demand for biopreservation tools, expansion into new markets, and strategic partnerships. Growing adoption of regenerative medicine, cell and gene therapies, and personalized medicine also contribute to growth. Additionally, BioLife Solutions' investments in technology and infrastructure, as well as its strong sales and marketing efforts, support the segment's rapid expansion.
Segment n°4 -> Biostorage Services - Rental
Expected Growth : 15.5 %
What the company do ?
BioLife Solutions' Biostorage Services - Rental provides a flexible, cost-effective solution for storing biological materials, including cells, tissues, and biomolecules, at ultra-low temperatures.
Why we expect these perspectives ?
Biostorage Services' 15.5% growth is driven by increasing demand for cryopreservation and cold chain logistics in cell and gene therapy, regenerative medicine, and biobanking. Expanding customer base, strategic partnerships, and investments in capacity expansion and technology advancements also contribute to growth.
Segment n°5 -> Biostorage Services - Product
Expected Growth : 16.5 %
What the company do ?
Biostorage Services from BioLife Solutions, Inc. provides secure, temperature-controlled storage and logistics for biological materials, including cells, tissues, and biomolecules.
Why we expect these perspectives ?
Biostorage Services' 16.5% growth is driven by increasing demand for biopreservation tools, expansion into new markets, and strategic partnerships. Growing adoption of regenerative medicine, cell and gene therapies, and personalized medicine also contribute to growth. Additionally, BioLife Solutions' investments in technology and infrastructure, as well as its strong sales and marketing efforts, support the segment's rapid expansion.
Segment n°6 -> Freezer and Thaw - Service
Expected Growth : 14.5 %
What the company do ?
BioLife Solutions' Freezer and Thaw - Service preserves and thaws biological samples, ensuring viability and integrity for research, clinical, and commercial applications.
Why we expect these perspectives ?
BioLife Solutions' Freezer and Thaw service growth is driven by increasing demand for regenerative medicine, cell and gene therapy, and biobanking. The 14.5% growth rate is also fueled by the company's expanding customer base, strategic partnerships, and investments in product development and commercialization.
Biolife Solutions, Inc. Products
| Product Range | What is it ? |
|---|---|
| CryoStor | A cryopreservation freeze media used to preserve living cells and tissues at very low temperatures. |
| HypoThermosol | A hypothermic storage solution used to preserve organs and tissues at low temperatures. |
| CryoStor CS10 | A cryopreservation freeze media used to preserve stem cells and other cell types. |
| BioLife's Custom Biopreservation Media | Customized biopreservation media solutions for specific cell and tissue types. |
| evo Cold Chain 2-8°C Shipper | A cold chain shipping solution used to transport temperature-sensitive biologics. |
BioLife Solutions, Inc.'s Porter Forces
Threat Of Substitutes
BioLife Solutions, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotechnology industry.
Bargaining Power Of Customers
BioLife Solutions, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are critical to its customers' operations, making it difficult for customers to negotiate prices.
Bargaining Power Of Suppliers
BioLife Solutions, Inc. relies on a few key suppliers for its raw materials, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate prices mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements and regulatory hurdles. This makes it difficult for new entrants to enter the market and compete with established players like BioLife Solutions, Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players competing for market share. BioLife Solutions, Inc. faces intense competition from companies with similar products and services, which can lead to pricing pressure and reduced market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 7.74% |
| Debt Cost | 4.23% |
| Equity Weight | 92.26% |
| Equity Cost | 12.38% |
| WACC | 11.75% |
| Leverage | 8.39% |
BioLife Solutions, Inc. : Quality Control
BioLife Solutions, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| EKSO | Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, … |
| ATRI | Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products … |
| ANGO | AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use … |
| STAA | STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The … |
| STXS | Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Atrion
A-Score
1-Year Total Return ->
🥈
BioLife Solutions
A-Score
1-Year Total Return ->
🥉
STAAR Surgical
A-Score
1-Year Total Return ->
4
Stereotaxis
A-Score
1-Year Total Return ->
5
AngioDynamics
A-Score
1-Year Total Return ->
6
